One thought I have had that is not really germane

One thought I have had that is not really germane to the questions of the day but is more of a mental exercise is why didn't the company first go after the dermatology related indications as they would be dealing with a topical cream that is pretty easy to devise compared to a pill (according to what I have been told), a topical cream would not cause systemic problems needing careful analysis, the revenue targets are larger than IBD, and it seems overall the movement forward would have been quicker than attacking the IBD revenue indication?

Rest of the year will be critical to the company IMO as many think a deal is a very near term possibility while I tend to believe it may still be a bit further in the future. Hoping they are correct as to this matter as finances still staring us square in the face.

Keeping the lab space another head scratcher for me but have to believe Leo knows what is best at the current time as to negotiations and keeping a strong position in them.

Still a lot of moving parts, hope they soon all fall into place and a well defined picture for IPIX becoming successful ensues.